CHMP says yes to Novartis's Jakavi, BMS/AZ's Forxiga and Takeda's Rienso
This article was originally published in Scrip
Three new drugs have this month won a green light from the European Medicine Agency's Committee for Medicinal Products for Human Use, while two others were again rebuffed.
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.